Lund, Sweden, June 24, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” has been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, […]
Lund, Sweden, 10 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Fredrik Röök has been appointed as VP Business Development effective 17th August. Mr Röök will report to CEO Renée Aguiar-Lucander. Read more…
The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission to EMA for conversion to full marketing authorization planned for Q4 2026 Lund, Sweden, May 27, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: […]
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. Lund, Sweden, 4 March 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been […]
